Every Form 4 that TEVA PHARM INDUS LTD (TEVJF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.
Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.
On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.
Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.
Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.
TEVA Pharmaceutical Industries Chief Accounting Officer Amir Weiss exercised 5,179 Restricted Share Units on March 3, 2026, converting them into 5,179 Ordinary Shares at a reported price of $0.0000 per share. Following the conversion, he held 10,829 Ordinary Shares directly and 5,180 restricted share units remain scheduled to vest on March 3, 2027. The restricted share units were originally granted on March 3, 2023, with 5,179 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.
He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.
Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.
Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.
Teva Pharmaceutical Industries Ltd reported insider transactions by President and CEO Francis Richard on March 3, 2026. He exercised restricted share units into ordinary shares and then sold a portion of the resulting holdings.
The filing shows exercises or conversions of restricted share units into 67,231 and 891,315 ordinary shares at a stated price of $0.0000 per share, and open-market sales totaling 442,935 ordinary shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. The transactions were effected under a Rule 10b5-1 trading plan, and some shares were sold to cover tax withholding obligations related to vesting restricted share units.
After these transactions, Richard directly held 1,121,382 ordinary shares. Footnotes explain that restricted share units were originally granted or earned based on performance and time-based vesting criteria and that each unit represents a right to receive one ordinary share or its cash value.
Teva Pharmaceutical Industries Ltd. executive vice president and chief financial officer Eliyahu Sharon Kalif exercised restricted share units into ordinary shares on March 3, 2026.
He converted 49,800 and 141,478 restricted share units, resulting in 248,756 ordinary shares held directly as of that date.
Teva Pharmaceutical Industries’ President and CEO, Richard Francis, reported a combination of share exercises and sales. On February 15, 2026, he exercised restricted share units into ordinary shares and then sold a total of 447,778 ordinary shares at a weighted average price of $34.2241 per share, in multiple trades between $34.015 and $34.51.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025. Footnotes state that some of the vested shares, including performance-based awards, were sold to cover tax withholding obligations. After these moves, he directly owned 605,771 Teva ordinary shares.
Teva Pharmaceutical Industries executive Eliyahu Sharon Kalif, EVP and Chief Financial Officer, received 141,478 restricted share units on January 27, 2026. These units were granted at a price of $0.00 per unit.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The units were issued after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026. Each unit represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.
The restricted share units were earned after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. Following this award, Hughes directly beneficially owned 141,478 derivative securities tied to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. reported that Exec. VP, European Commercial, Richard Daniell was granted 141,478 restricted share units (RSUs) on January 27, 2026. Each RSU represents a right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The RSUs were earned upon satisfaction of performance criteria tied to earlier performance share units and remain subject to time-based vesting. They are scheduled to vest on March 3, 2026. The underlying ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.
Teva Pharmaceutical Industries’ President and CEO Richard D. Francis received new equity-based awards in the form of restricted share units (RSUs). On January 27, 2026, he was granted 620,110 RSUs that were earned after meeting performance criteria and will continue to vest on February 15, 2026. He was also granted an additional 891,315 RSUs that were earned upon satisfaction of separate performance goals and will vest on March 3, 2026.
Each RSU represents a contingent right to receive either one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. These awards are held directly by Francis and compensate performance while tying a significant portion of his compensation to Teva’s equity.
An officer of Teva Pharmaceutical Industries Ltd. reported selling 12,300 ordinary shares on 12/16/2025 at a weighted average price of $30.2036 per share. The filing identifies the insider as the company’s Chief Accounting Officer, and shows that 5,650 shares were beneficially owned directly after the transaction. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share. The sale was executed in multiple trades at prices ranging from $30.20 to $30.205 per share.
Teva Pharmaceutical Industries Ltd. director Roberto Mignone reported selling 77,400 Ordinary Shares of Teva on 12/16/2025 at a weighted average price of $30.2409 per share. The filing notes that Teva’s Ordinary Shares may be represented by American Depositary Shares, each currently equal to one Ordinary Share.
After this sale, the report shows Mr. Mignone with 105,315 Ordinary Shares held directly. It also shows 367,600 Ordinary Shares held of record by Swiftcurrent Master Fund Ltd., for which Bridger Management, LLC is investment adviser and Mr. Mignone is manager. Under SEC rules he may be deemed to beneficially own those shares, but he disclaims beneficial ownership except to the extent of his indirect pecuniary interest.
Teva Pharmaceutical Industries executive exercises options and sells shares
On December 9, 2025, a Teva Pharmaceutical Industries Ltd. executive, identified as an officer serving as Exec. VP, European Commercial, reported multiple equity transactions. The executive exercised 100,457 stock options at an exercise price of $18.61 per share and another 15,011 stock options at an exercise price of $16.99 per share, receiving the same number of Teva ordinary shares. On the same day, the executive sold 115,468 ordinary shares at a weighted average price of $28.6757 per share, leaving 48,384 ordinary shares beneficially owned directly after the transactions. The filing notes that Teva ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.
That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of $26.0301 per share, with individual trades ranging from $26.03 to $26.035.
After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.
Teva Pharmaceutical Industries Ltd. (TEVA) reported an insider stock sale by its EVP, Head of U.S. Commercial. On 11/14/2025, the executive sold 30,000 Ordinary Shares in an open market transaction at a price of $25.1107 per share, reported under transaction code "S" for a sale. After this transaction, the executive beneficially owns 28,384 Ordinary Shares, held directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA Pharmaceutical Industries (TEVA) reported an insider transaction by director Roberto Mignone. On 11/06/2025, he sold 200,000 Ordinary Shares (transaction code S) at a weighted average price of $24.1094.
Following the sale, he beneficially owned 495,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that TEVA’s Ordinary Shares may be represented by ADSs, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries (TEVA) disclosed an insider transaction on Form 4. Chief Accounting Officer Amir Weiss sold 12,300 ordinary shares on 11/06/2025 at a weighted average price of $24.4361, with trades ranging from $24.435 to $24.455. Following the sale, he beneficially owns 17,950 shares, held directly. The filing notes that Teva’s ordinary shares may be represented by ADSs, each currently equal to one ordinary share.